By Eytan Abraham, Ph.D., VP Business Head of Cell Therapy, Gene Therapy, and Nucleic Acid Franchises, Resilience
While cell therapies comprise a small segment of therapeutics, the landscape is rapidly changing, with over 1,000 ongoing clinical trials and several recent commercial approvals. Scalable biomanufacturing is crucial to making these therapies accessible to more patients, but gaps in capacity and technologies are holding them back from wide adoption. Eytan Abraham discusses biomanufacturing bottlenecks and how to overcome them.
